Elashoff RM - Search Results

1

CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer.

Habal N, Gupta RK, Bilchik AJ, Yee R, Leopoldo Z, Ye W, Elashoff RM, Morton DL. Habal N, et al. Among authors: elashoff rm. Ann Surg Oncol. 2001 Jun;8(5):389-401. doi: 10.1007/s10434-001-0389-6. Ann Surg Oncol. 2001. PMID: 11407512

2

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R, et al. Morton DL, et al. Ann Surg. 1992 Oct;216(4):463-82. doi: 10.1097/00000658-199210000-00010. Ann Surg. 1992. PMID: 1417196 Free PMC article. Clinical Trial.

3

Increased incidence of second primary melanoma in patients with a previous cutaneous melanoma.

DiFronzo LA, Wanek LA, Elashoff R, Morton DL. DiFronzo LA, et al. Ann Surg Oncol. 1999 Oct-Nov;6(7):705-11. doi: 10.1007/s10434-999-0705-0. Ann Surg Oncol. 1999. PMID: 10560858

4

Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes.

Morton DL, Hsueh EC, Essner R, Foshag LJ, O'Day SJ, Bilchik A, Gupta RK, Hoon DS, Ravindranath M, Nizze JA, Gammon G, Wanek LA, Wang HJ, Elashoff RM. Morton DL, et al. Among authors: elashoff rm. Ann Surg. 2002 Oct;236(4):438-48; discussion 448-9. doi: 10.1097/00000658-200210000-00006. Ann Surg. 2002. PMID: 12368672 Free PMC article. Clinical Trial.

5

Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine.

Wascher RA, Morton DL, Kuo C, Elashoff RM, Wang HJ, Gerami M, Hoon DS. Wascher RA, et al. Among authors: elashoff rm. J Clin Oncol. 2003 Jul 1;21(13):2558-63. doi: 10.1200/JCO.2003.06.110. J Clin Oncol. 2003. PMID: 12829676 Clinical Trial.

6

Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma.

Morton DL, Hoon DS, Nizze JA, Foshag LJ, Famatiga E, Wanek LA, Chang C, Irie RF, Gupta RK, Elashoff R. Morton DL, et al. Ann N Y Acad Sci. 1993 Aug 12;690:120-34. doi: 10.1111/j.1749-6632.1993.tb44002.x. Ann N Y Acad Sci. 1993. PMID: 8368731 Clinical Trial. No abstract available.

7

Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients?

Hoon DS, Okamoto T, Wang HJ, Elashoff R, Nizze AJ, Foshag LJ, Gammon G, Morton DL. Hoon DS, et al. J Clin Oncol. 1998 Apr;16(4):1430-7. doi: 10.1200/JCO.1998.16.4.1430. J Clin Oncol. 1998. PMID: 9552048

8

Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial.

Hoshimoto S, Shingai T, Morton DL, Kuo C, Faries MB, Chong K, Elashoff D, Wang HJ, Elashoff RM, Hoon DS. Hoshimoto S, et al. Among authors: elashoff rm, elashoff d. J Clin Oncol. 2012 Nov 1;30(31):3819-26. doi: 10.1200/JCO.2011.40.0887. Epub 2012 Sep 24. J Clin Oncol. 2012. PMID: 23008288 Free PMC article. Clinical Trial.

9

Thermal dose-response of magnetic-induction thermoradiotherapy.

Storm FK, Elashoff RM, Baker HW, Scanlon EF, Drury B, Lee M, Roe D, Morton DL. Storm FK, et al. Among authors: elashoff rm. J Surg Oncol. 1988 Oct;39(2):79-83. doi: 10.1002/jso.2930390203. J Surg Oncol. 1988. PMID: 3172795

10

Identifying predictive factors in melanoma progression.

Dabrowska DM, Elashoff RM, Ho W, Morton DL. Dabrowska DM, et al. Among authors: elashoff rm. Oncol Rep. 1998 May-Jun;5(3):569-75. doi: 10.3892/or.5.3.569. Oncol Rep. 1998. PMID: 9538154

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

207 results

Search Page